Business Context and Reporting Period
This Form 8-K filing by AnaptysBio, Inc. (ANAB) was submitted on August 16, 2019, reporting corporate governance changes effective as of that date. The company is a Delaware corporation with principal executive offices in San Diego, California, and its common stock trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on personnel changes and associated compensatory arrangements.
Material Changes
- Departure of CFO: Dominic Piscitelli resigned as Chief Financial Officer, effective September 9, 2019.
- Appointment of Interim CFO: Eric Loumeau was appointed immediately as interim Chief Financial Officer and General Counsel.
- Compensatory Arrangement: In connection with his appointment, Mr. Loumeau was granted an option to purchase 17,500 shares of common stock at the fair market value on the grant date.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to the background of the new interim CFO, noting his experience in corporate finance, having raised over $5 billion in securities offerings, and his prior roles at Otonomy, Inc., Rempex Pharmaceuticals, Inc., and Hollis-Eden Pharmaceuticals, Inc.
Investor Verification Checklist
- Verify the effective date of the CFO transition (September 9, 2019) and the interim status of the new appointee.
- Confirm the terms of the stock option grant (17,500 shares) and the exercise price mechanism.
- Review subsequent filings to determine if a permanent CFO has been appointed to replace the interim officer.
- Check for any related party transaction disclosures regarding Mr. Loumeau's prior service as General Counsel since August 2018.